Embryo Transfer — Cost, Top Hospitals & Success Rates | MyMedicPlus

Embryo transfer (ET) is the concluding and most critical step of in vitro fertilisation (IVF), intracytoplasmic sperm injection (ICSI), and frozen embryo transfer (FET) cycles. It involves the transcervical placement of one or more embryos into the uterine cavity using a fine, flexible catheter guided by ultrasound. Despite being technically straightforward compared to egg retrieval, embryo transfer technique significantly influences cycle success — variations in catheter type, uterine depth of placement, and the clinician's experience all affect implantation rates. Embryos are transferred on day 2–3 (cleavage stage, 2–8 cells) or, increasingly, on day 5–6 as blastocysts, which have higher implantation potential and allow preimplantation genetic testing (PGT-A) to select euploid embryos.

Fresh ET is performed 3–6 days after egg retrieval when the embryo and endometrial development are synchronised. Frozen embryo transfer (FET) involves transferring cryopreserved embryos in a subsequent hormonally prepared cycle — this approach allows embryo banking, PGT-A screening, and avoidance of ovarian hyperstimulation syndrome. FET success rates now equal or exceed fresh ET in most centres. The number of embryos transferred is guided by age, embryo quality, and prior cycle history — single embryo transfer (SET) is strongly recommended for blastocysts in patients under 38 to minimise multiple pregnancy risk while maintaining cumulative success rates.

Embryo transfer is indicated for any patient undergoing IVF or ICSI cycles for any infertility diagnosis. Tubal factor infertility (blocked or absent fallopian tubes) was the original IVF indication and remains a prime candidate for ET-based ART. Male factor infertility — oligospermia, asthenospermia, azoospermia — treated with ICSI leads to ET. Unexplained infertility, ovulatory dysfunction, diminished ovarian reserve, endometriosis, and recurrent implantation failure (RIF) all culminate in embryo transfer as the treatment endpoint.

Donor egg cycles (using eggs from a younger donor for older recipients or women with premature ovarian insufficiency) require embryo transfer to the recipient's uterus. Gestational surrogacy requires transfer of the intended parents' embryos into the surrogate's uterus. Fertility preservation patients — cancer patients who froze embryos before chemotherapy, or women who froze embryos for elective reasons — require FET when ready to conceive. PGT-A tested cycles transfer only euploid embryos, which is particularly relevant for patients with recurrent miscarriage, advanced maternal age, or prior chromosomally abnormal pregnancies.

Any patient who has completed an IVF stimulation cycle and has viable embryos available is a candidate for embryo transfer. For fresh ET, the endometrium must be adequately prepared — minimum 7 mm thickness with a trilaminar pattern on ultrasound, confirmed progesterone levels indicating appropriate luteal support. Patients who develop OHSS risk (oestradiol above 4,000 pg/mL, excessive follicle number) may have their fresh ET cancelled in favour of freeze-all with FET in a subsequent cycle.

For FET, the uterine cavity must be normal — submucosal fibroids, intrauterine adhesions (Asherman syndrome), endometrial polyps, or hydrosalpinx (which reduces implantation rates by approximately 50%) must be treated before transfer. Endometrial receptivity can be assessed by the ERA (Endometrial Receptivity Analysis) test in patients with recurrent implantation failure to personalise the progesterone-to-transfer window. There is no strict upper age limit for ET using donor eggs, though uterine capacity and cardiovascular assessment are recommended in women over 50. Progesterone support (vaginal pessaries or injections) is required from the day of egg retrieval (fresh) or from the initiation of progesterone in FET cycles.

Fresh embryo transfer: performed 3 days (cleavage stage) or 5–6 days (blastocyst stage) after egg retrieval, using a soft Wallace or Cook catheter loaded with embryo(s) in 20 microlitres of culture medium. Abdominal ultrasound guidance ensures catheter tip placement 1.0–1.5 cm from the uterine fundus for optimal implantation. A difficult transfer due to cervical stenosis may require cervical dilation or use of a rigid outer sheath — techniques that increase implantation failure risk and should be identified and addressed proactively.

Frozen embryo transfer (FET) in a natural cycle: for women with regular ovulation, monitoring follicular growth and LH surge, then timed progesterone supplementation aligned to natural ovulation, avoids exogenous hormone exposure. Artificial FET cycle: administered oestrogen (oral, transdermal, or vaginal) builds endometrial thickness, followed by progesterone initiation timed to transfer date — provides flexible scheduling and precise endometrial preparation. Modified natural cycle combines ovulation trigger with progesterone support.

Preimplantation genetic testing (PGT-A/PGT-M) cycles biopsy 5–8 trophectoderm cells from blastocysts on day 5–6, send for next-generation sequencing, and transfer only chromosomally normal embryos in subsequent FET cycles — reducing miscarriage risk by 50% and improving live birth rates per transfer in appropriate patients. Single embryo transfer (SET) is the standard of care for blastocysts in patients under 38 with good prognosis.

Embryo transfer achieves live birth rates of 35–55% per transfer for women under 35 using blastocyst SET, based on 2023 SART and ESHRE registry data. In donor egg FET cycles, live birth rates reach 50–65% irrespective of recipient age due to egg quality being the dominant determinant. Blastocyst transfer offers superior implantation rates versus cleavage-stage transfer (48% vs 32% per transfer in systematic reviews) by allowing natural embryo selection through extended culture.

Frozen embryo transfer outcomes now match or exceed fresh ET across age groups, with the additional advantages of eliminating OHSS risk, allowing genetic testing, and enabling flexible family planning through embryo banking. PGT-A in high-risk groups (recurrent miscarriage, advanced maternal age) reduces miscarriage rates from approximately 30% to under 10% per transfer. The cumulative live birth rate after multiple FET cycles from a single stimulation cycle now exceeds 60–70% for women under 40 at high-quality IVF centres.

Embryo transfer itself is a low-risk, generally painless procedure — significant complications directly attributable to transfer are rare. The primary risks of IVF/ET cycles relate to ovarian stimulation (OHSS), multiple pregnancy, and cycle failure. Multiple pregnancy from multi-embryo transfer carries risks of prematurity, low birth weight, gestational diabetes, and pre-eclampsia — the shift to elective SET has substantially reduced but not eliminated this risk (approximately 5–7% of blastocyst SET cycles still result in identical twins).

Implantation failure (biochemical pregnancy, early pregnancy loss, or no implantation) occurs in approximately 50–65% of transfer cycles for women under 35 and increases substantially with age. Ectopic pregnancy risk is approximately 2–3% of IVF pregnancies. Post-transfer progesterone support (vaginal pessaries or injections) can cause local irritation, bloating, and mood changes. Endometrial scratching, sometimes offered for recurrent implantation failure, has inconsistent evidence and may marginally increase or decrease success rates depending on the protocol.

Following embryo transfer, patients are advised to rest for 30 minutes in the clinic before discharge. Complete bed rest is not recommended by evidence — normal light activity does not impair implantation. Progesterone supplementation continues until serum beta-hCG testing 10–14 days after transfer. A positive beta-hCG is followed by repeat testing at 48 hours to confirm doubling, then transvaginal ultrasound at 6–7 weeks to confirm intrauterine location and fetal cardiac activity.

For FET cycles, oestrogen and progesterone support continue until 10–12 weeks of gestation, when placental steroidogenesis takes over. All patients receive individualised luteal phase support protocols from their reproductive endocrinologist. Progesterone levels are monitored to ensure adequate supplementation. Patients with recurrent implantation failure may have endometrial preparation modified — extended endometrial priming, ERA-guided timing, or adjunctive treatments (GCSF, aspirin, hydroxyprogesterone) evaluated in specialist centres.

Embryo transfer costs are generally included within the overall IVF or FET cycle fee. In the United States, a single IVF cycle including egg retrieval, embryo culture, and fresh ET costs USD 12,000–20,000; FET cycles cost USD 3,000–5,000 when embryos are already banked. In the UK, FET cycle costs range GBP 1,500–3,500. PGT-A testing adds USD 3,000–6,000 per batch of embryos biopsied.

Medical tourism offers substantial cost savings: India offers complete IVF-fresh ET packages including medications for USD 2,500–5,000; FET cycles USD 800–1,500. Thailand packages cost USD 4,000–8,000 for fresh cycles. Spain and Czech Republic offer donor egg FET at EUR 5,000–8,000 (fresh donor) and EUR 2,000–3,000 (frozen donor), representing 60–70% savings versus US pricing. Clinics in Istanbul, Bangkok, Mumbai, and Prague have ESHRE-compliant laboratories with internationally trained embryologists, offering competitive outcomes at significantly lower cost.

When multiple IVF-ET cycles fail despite good embryo quality, recurrent implantation failure (RIF) workup guides further management. Alternatives include uterine cavity evaluation and treatment (hysteroscopy to correct anatomical barriers), endometrial receptivity testing (ERA) to optimise timing, and immunological screening (NK cell assays, HLA matching) with targeted treatments in specialist centres.

For patients with failed FET cycles using own eggs, donor egg cycles with a younger donor's eggs dramatically improve success rates. Gestational surrogacy is an alternative when uterine factors prevent successful ET (Müllerian anomalies, fibroids requiring hysterectomy, repeated implantation failure after extensive investigation). Adoption represents a non-medical alternative to parenthood. Natural cycle monitoring and timed intercourse — for couples with unexplained infertility — is an appropriate lower-intervention first step before escalating to IVF-ET.